Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.38 |
| ▸ | BRAF | P15056 | 5/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343990 | 0.82 | MAP2K1 (0.46) | MAP2K1BRAFMAP2K2ABCB11NQO2 | |
| SCHEMBL13063819 | 0.81 | MAP2K1 (0.36) | MAP2K1BRAFMAP2K2ABCB11NQO2 | |
| SCHEMBL3801305 | 0.76 | MAP2K1 (0.60) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL1342894 | 0.74 | MAP2K1 (0.47) | MAP2K1BRAFMAP2K2ABCB11NQO2 | |
| SCHEMBL13063593 | 0.73 | MAP2K1 (0.39) | MAP2K1MAP2K2 | |
| SCHEMBL3803473 | 0.72 | MAP2K1 (0.43) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL13063577 | 0.71 | MAP2K1 (0.41) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL29413475 | 0.70 | MAP2K1 (0.58) | MAP2K1BRAFMAP2K2ABCB11NQO2 | |
| SCHEMBL1342640 | 0.70 | MAP2K1 (0.58) | MAP2K1BRAFMAP2K2ABCB11NQO2 | |
| SCHEMBL13063552 | 0.69 | MAP2K1 (0.58) | MAP2K1MAP2K2MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010145197-A1 | NOVEL 6-ARYLAMINO PYRIDONE SULFONAMIDES AND 6-ARYLAMINO PYRAZINONE SULFONAMDIES AS MEK INHIBITORS | CHEMIZON (BEIJING), LTD. (CN) | 2010-12-23 | — | — | WO | disclosed |